Edge Therapeutics, Inc. (NASDAQ:EDGE) insider Brian A. Leuthner sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $10.96, for a total transaction of $82,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Edge Therapeutics, Inc. (EDGE) opened at 11.04 on Friday. Edge Therapeutics, Inc. has a 52-week low of $7.30 and a 52-week high of $13.50. The stock’s market capitalization is $340.60 million. The stock has a 50 day moving average of $10.22 and a 200 day moving average of $9.98.

Edge Therapeutics (NASDAQ:EDGE) last posted its quarterly earnings results on Tuesday, August 1st. The biotechnology company reported ($0.44) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.44). Analysts forecast that Edge Therapeutics, Inc. will post ($1.87) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/brian-a-leuthner-sells-7500-shares-of-edge-therapeutics-inc-edge-stock/1612481.html.

Several equities research analysts have recently commented on the stock. Zacks Investment Research raised shares of Edge Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 29th. BidaskClub cut shares of Edge Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, August 14th.

Several hedge funds and other institutional investors have recently bought and sold shares of EDGE. Janus Henderson Group PLC bought a new position in shares of Edge Therapeutics in the second quarter worth about $21,962,000. State Street Corp grew its holdings in shares of Edge Therapeutics by 16.3% in the second quarter. State Street Corp now owns 277,352 shares of the biotechnology company’s stock worth $2,847,000 after purchasing an additional 38,909 shares during the last quarter. Goldman Sachs Group Inc. bought a new position in shares of Edge Therapeutics in the second quarter worth about $374,000. Renaissance Technologies LLC bought a new position in shares of Edge Therapeutics in the first quarter worth about $297,000. Finally, Franklin Resources Inc. grew its holdings in shares of Edge Therapeutics by 1.1% in the second quarter. Franklin Resources Inc. now owns 2,663,123 shares of the biotechnology company’s stock worth $27,324,000 after purchasing an additional 30,100 shares during the last quarter. Hedge funds and other institutional investors own 49.38% of the company’s stock.

Edge Therapeutics Company Profile

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Insider Buying and Selling by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Receive News & Ratings for Edge Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.